Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations

Introduction: V600E BRAF mutation is an established driver mutation in a variety of tumors. Vemurafenib is a selective inhibitor of the BRAF V600E kinase, known to be highly effective in BRAF V600E-positive metastatic melanoma. As a single agent, vemurafenib is relatively ineffective in other V600E-...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Cancer Biol Ther
Main Authors: Ofir Dovrat, Tali, Sokol, Ethan, Frampton, Garrett, Shachar, Eliya, Pelles, Sharon, Geva, Ravit, Wolf, Ido
פורמט: Artigo
שפה:Inglês
יצא לאור: Taylor & Francis 2018
נושאים:
Bedside to Bench Report
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6300338/
https://ncbi.nlm.nih.gov/pubmed/30036146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2018.1480289
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים